Tag: generic drug entry
Discover how pharmaceutical companies use secondary patents and patent thickets to extend market exclusivity and delay generic competition long after primary patents expire.
- Read More
Paragraph IV certification under the Hatch-Waxman Act allows generic drug makers to challenge brand-name patents and enter the market faster. Learn how this legal tool drives down drug prices and what makes it unique to the U.S.